AstraZeneca’s Outlicensing Tactics Make It Top Dealmaker
Executive Summary
Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.
You may also be interested in...
Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
Nektar Pins Falling Cancer Response Rate On Manufacturing Problem
A post-hoc analysis linked “physical differences” in two lots of Nektar’s drug to lower efficacy when given in combination with Bristol-Myers Squibb’s Opdivo. Nektar’s share price tumbled following the update.
Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain
The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.